Regarding facility-related factors, HER2-targeted therapy patients were more likely to be treated at academic (36.2% vs. 26.3%, p < 0.001) and comprehensive cancer centers (36.0% vs. 40.3%, p < 0.001), and less likely to be treated at community facilities (7.2% vs. 12.1%, p < 0.001). Here, ERBB2 is linked to cancer.